Salarius Pharmaceuticals Inc. (NASDAQ:SLRX) went up by 8.44% from its latest closing price compared to the recent 1-year high of $1.51. The company’s stock price has collected -24.92% of loss in the last five trading sessions.
Is It Worth Investing in Salarius Pharmaceuticals Inc. (NASDAQ :SLRX) Right Now?
Plus, the 36-month beta value for SLRX is at 1.43. Opinions of the stock are interesting as 1 analysts out of 1 who provided ratings for Salarius Pharmaceuticals Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $5.00, which is $4.08 above the current price. SLRX currently public float of 45.01M and currently shorts hold a 1.34% ratio of that float. Today, the average trading volume of SLRX was 603.58K shares.
SLRX’s Market Performance
SLRX stocks went down by -24.92% for the week, with a monthly drop of -57.55% and a quarterly performance of -68.43%, while its annual performance rate touched -86.09%. The volatility ratio for the week stands at 16.04% while the volatility levels for the past 30 days are set at 12.36% for Salarius Pharmaceuticals Inc.. The simple moving average for the period of the last 20 days is -32.30% for SLRX stocks with a simple moving average of -72.70% for the last 200 days.
Analysts’ Opinion of SLRX
Many brokerage firms have already submitted their reports for SLRX stocks, with Ladenburg Thalmann repeating the rating for SLRX by listing it as a “Buy.” The predicted price for SLRX in the upcoming period, according to Ladenburg Thalmann is $3.80 based on the research report published on April 27th of the previous year 2020.
SLRX Trading at -48.56% from the 50-Day Moving Average
After a stumble in the market that brought SLRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -88.51% of loss for the given period.
Volatility was left at 12.36%, however, over the last 30 days, the volatility rate increased by 16.04%, as shares sank -51.99% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -57.47% lower at present.
During the last 5 trading sessions, SLRX fell by -16.71%, which changed the moving average for the period of 200-days by -80.00% in comparison to the 20-day moving average, which settled at $0.2468. In addition, Salarius Pharmaceuticals Inc. saw -67.72% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at SLRX starting from Rosenblum Mark J, who purchase 76,246 shares at the price of $0.39 back on Mar 03. After this action, Rosenblum Mark J now owns 110,319 shares of Salarius Pharmaceuticals Inc., valued at $29,812 using the latest closing price.
Arthur David J., the Chief Executive Officer of Salarius Pharmaceuticals Inc., purchase 139,488 shares at $0.39 during a trade that took place back on Mar 03, which means that Arthur David J. is holding 249,674 shares at $54,540 based on the most recent closing price.
Stock Fundamentals for SLRX
Current profitability levels for the company are sitting at:
- -696.27 for the present operating margin
- +98.96 for the gross margin
The net margin for Salarius Pharmaceuticals Inc. stands at -693.84. Equity return is now at value -29.00, with -27.90 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 14.29.